Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) accounts for 10% of hematologic malignancies. CLL is a malignancy of CD5+ B cells and it is characterized by the accumulation of small, mature-appearing neoplastic lymphocytes in the blood, bone marrow, and secondary lymphoid tissues. In the present case, a middle-...

Descripción completa

Detalles Bibliográficos
Autores principales: Maharaj, Dipnarine, Srinivasan, Gayathri, Abreu, Maria M., Ko, Meng-Wei, Jewett, Anahid, Gouvea, Jacqueline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822209/
https://www.ncbi.nlm.nih.gov/pubmed/33375215
http://dx.doi.org/10.3390/cells10010010
_version_ 1783639580720758784
author Maharaj, Dipnarine
Srinivasan, Gayathri
Abreu, Maria M.
Ko, Meng-Wei
Jewett, Anahid
Gouvea, Jacqueline
author_facet Maharaj, Dipnarine
Srinivasan, Gayathri
Abreu, Maria M.
Ko, Meng-Wei
Jewett, Anahid
Gouvea, Jacqueline
author_sort Maharaj, Dipnarine
collection PubMed
description Chronic lymphocytic leukemia (CLL) accounts for 10% of hematologic malignancies. CLL is a malignancy of CD5+ B cells and it is characterized by the accumulation of small, mature-appearing neoplastic lymphocytes in the blood, bone marrow, and secondary lymphoid tissues. In the present case, a middle-aged female patient with poor prognosis unmutated IGHV CLL achieved cytogenetic and molecular remission with minimal adverse events following six cycles of low dose recombinant human IL-2 (rIL-2) in combination with low dose targeted venetoclax. Personalized low dose rIL-2 in combination with either lenalidomide or venetoclax mediates natural killer stimulation and is an effective non-toxic immunotherapy administered in the outpatient setting for poor prognosis CLL.
format Online
Article
Text
id pubmed-7822209
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78222092021-01-23 Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia Maharaj, Dipnarine Srinivasan, Gayathri Abreu, Maria M. Ko, Meng-Wei Jewett, Anahid Gouvea, Jacqueline Cells Case Report Chronic lymphocytic leukemia (CLL) accounts for 10% of hematologic malignancies. CLL is a malignancy of CD5+ B cells and it is characterized by the accumulation of small, mature-appearing neoplastic lymphocytes in the blood, bone marrow, and secondary lymphoid tissues. In the present case, a middle-aged female patient with poor prognosis unmutated IGHV CLL achieved cytogenetic and molecular remission with minimal adverse events following six cycles of low dose recombinant human IL-2 (rIL-2) in combination with low dose targeted venetoclax. Personalized low dose rIL-2 in combination with either lenalidomide or venetoclax mediates natural killer stimulation and is an effective non-toxic immunotherapy administered in the outpatient setting for poor prognosis CLL. MDPI 2020-12-22 /pmc/articles/PMC7822209/ /pubmed/33375215 http://dx.doi.org/10.3390/cells10010010 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Maharaj, Dipnarine
Srinivasan, Gayathri
Abreu, Maria M.
Ko, Meng-Wei
Jewett, Anahid
Gouvea, Jacqueline
Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia
title Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia
title_full Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia
title_fullStr Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia
title_full_unstemmed Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia
title_short Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia
title_sort molecular remission using low-dose immunotherapy with minimal toxicities for poor prognosis ighv—unmutated chronic lymphocytic leukemia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822209/
https://www.ncbi.nlm.nih.gov/pubmed/33375215
http://dx.doi.org/10.3390/cells10010010
work_keys_str_mv AT maharajdipnarine molecularremissionusinglowdoseimmunotherapywithminimaltoxicitiesforpoorprognosisighvunmutatedchroniclymphocyticleukemia
AT srinivasangayathri molecularremissionusinglowdoseimmunotherapywithminimaltoxicitiesforpoorprognosisighvunmutatedchroniclymphocyticleukemia
AT abreumariam molecularremissionusinglowdoseimmunotherapywithminimaltoxicitiesforpoorprognosisighvunmutatedchroniclymphocyticleukemia
AT komengwei molecularremissionusinglowdoseimmunotherapywithminimaltoxicitiesforpoorprognosisighvunmutatedchroniclymphocyticleukemia
AT jewettanahid molecularremissionusinglowdoseimmunotherapywithminimaltoxicitiesforpoorprognosisighvunmutatedchroniclymphocyticleukemia
AT gouveajacqueline molecularremissionusinglowdoseimmunotherapywithminimaltoxicitiesforpoorprognosisighvunmutatedchroniclymphocyticleukemia

Ejemplares similares